JUBLPHARMA stock
JUBLPHARMA is showing a constructive news setup around Pharmaceuticals, with 1 recent story and improving sentiment breadth.
JUBLPHARMA has built a constructive coverage cluster in the last 1 day. The strongest recurring theme is Pharmaceuticals, while the current weighted impact score is +21 from 0 bullish, 1 bearish, and 0 neutral stories across 1 sources.
JUBLPHARMA is last saved at ₹946 with a day move of +1.72%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
This is a record of Jubilant Pharmova's financial performance. The company reported revenues of ₹1821.7 crore and a profit of ₹101.0 crore. This information helps you understand how much money the company made and how profitable it was during this period. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Economic Times · 7 days ago · 2 min read
Economic Times · 28 Aug 2026 · 2 min read
Economic Times · 11 Aug 2026 · 2 min read
How JUBLPHARMA stacks against related names in this news cluster
JUBLPHARMA has appeared across 1 recent stories from 1 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
JUBLPHARMA coverage is currently leaning bearish, with 0 bullish, 1 bearish, and 0 neutral analyzed stories in the recent window.
Recent JUBLPHARMA coverage is clustering around Pharmaceuticals. Related names showing up alongside JUBLPHARMA include the wider peer basket.
Use this page as a coverage hub for JUBLPHARMA: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.